12.03.07
David A. Dodd has been named president, chief executive officer and chairman at BioReliance Corp. From 2000 through 2006, Mr. Dodd served as president and chief executive officer of Serologicals Corp., a publicly traded company that was sold to Millipore Corporation in 2006 for $1.4 billion. From 1995 to 2000, he was pPresident and chief executive officer of Solvay Pharmaceuticals, a subsidiary of the Solvay Group. Mr. Dodd entered the pharmaceutical industry in 1977 with Abbott Laboratories and served at McDonnell-Douglas Healthcare Systems, Bristol-Myers Squibb and Wyeth. Mr. Dodd currently serves as non-executive chairman at Stem Cell Sciences plc.
"David brings an impressive record of maximizing the potential and competitive impact of the companies he manages," said David Burgstahler, a partner at Avista Capital Partners, the private equity firm that acquired BioReliance from Invitrogen in April 2007. "He is a compelling and focused leader with proven ability at not only expanding revenues and profits at a rapid pace, but at the same time building very strong organizations with dedicated management teams. We look forward to working with David to continue to advance BioReliance’s leadership in its industry space."
"David brings an impressive record of maximizing the potential and competitive impact of the companies he manages," said David Burgstahler, a partner at Avista Capital Partners, the private equity firm that acquired BioReliance from Invitrogen in April 2007. "He is a compelling and focused leader with proven ability at not only expanding revenues and profits at a rapid pace, but at the same time building very strong organizations with dedicated management teams. We look forward to working with David to continue to advance BioReliance’s leadership in its industry space."